^
almost3years
Methotrexate and Triptolide regulate Notch signaling pathway by targeting the Nedd4-Numb axis. (PubMed, Int Immunopharmacol)
Interestingly, we found that a monomeric drug, Triptolide, is capable of alleviating the inhibitory effect of MTX on Notch signaling pathway. This study promotes our understanding of MTX-mediated regulation of Notch signaling and could provide ideas to alleviate MTX-induced myelosuppression.
Journal
|
NOTCH1 (Notch 1)
|
methotrexate • TriptoSar (omtriptolide)
almost3years
Screening of major hepatotoxic components of Tripterygium wilfordii based on hepatotoxic injury patterns. (PubMed, BMC Complement Med Ther)
Parthenolide, triptolide, triptonide, celastrol, demethylzeylasteral, triptotriterpenic acid A and triptobenzene H might be the main hepatotoxic components of TwFH. Among them, only triptotriterpenic acid A presents direct hepatotoxicity. Triptobenzene H exerts indirect liver damage by activating macrophages. Parthenolide, triptolide, triptonide, celastrol, and demethylzeylasteral can directly and indirectly cause liver injury.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
|
TriptoSar (omtriptolide)
almost3years
Network pharmacology, molecular docking and bioinformatics reveal the mechanism of Tripterygii Wilfordii against Osteosarcoma. (PubMed, Medicine (Baltimore))
Upregulation of the cellular tumor antigen p53 (TP53) gene and downregulation of peroxisome proliferator-activated receptor gamma (PPARG) and signal transducer and activator of transcription 1-alpha/beta (STAT1) genes can prolong the survival time of patients with OS. Triptolide, kaempferol, and 5,8-Dihydroxy-7-(4-hydroxy-5 methyl-coumarin-3)-coumarin have a relatively high potential to become a treatment for patients with OS and improve 5-year survival of OS patients.
Journal
|
PPARG (Peroxisome Proliferator Activated Receptor Gamma) • STAT1 (Signal Transducer And Activator Of Transcription 1)
|
TriptoSar (omtriptolide)
3years
Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin. (PubMed, Mol Med Rep)
Notably, the present study showed that triptolide re‑sensitized DOX‑resistant leukemia cells to DOX. In conclusion, the present study indicated that Nrf2 served a critical role in leukemia cell resistance to DOX and triptolide‑induced ferroptosis and suggested a potential strategy of combination therapy using triptolide and DOX in leukemia treatment.
Journal
|
NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • GPX4 (Glutathione Peroxidase 4)
|
GPX4 expression
|
doxorubicin hydrochloride • TriptoSar (omtriptolide)
3years
Triptolide Inhibits the Biological Processes of HUVECs and HepG2 Cells via the Serine Palmitoyltransferase Long Chain Base Subunit 2/Sphingosine-1-Phosphate Signaling Pathway. (PubMed, Dis Markers)
In conclusion, SPTLC2 may be associated with the antivascular and antitumor effects of TP, and SPTLC2 is expected to become a new marker for tumor therapy. HUVECs can promote the proliferation, migration, and invasion of HepG2 cells, which may be related to the S1P/sphingosine-1-phosphate receptor (S1PR) signaling pathway.
Journal
|
S1PR1 (Sphingosine-1-Phosphate Receptor 1)
|
TriptoSar (omtriptolide)
3years
Triptolide-mediated downregulation of FLIP in hepatoma cells occurs at the post-transcriptional level independently of proteasome-mediated pathways. (PubMed, Med Oncol)
Subsequently, we showed that TPL reduced FLIP level in a transcription- and degradation-independent mechanism. Our findings suggest that TPL induces loss of FLIP at the post-transcriptional level independently of proteasome-mediated pathway, an additional mechanism of TPL sensitizing cancer cells to TNF-α-induced apoptosis.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • BIRC3 (Baculoviral IAP repeat containing 3) • CASP8 (Caspase 8)
|
TriptoSar (omtriptolide)
3years
A mitochondria-targeted nano-platform for pancreatic cancer therapy. (PubMed, Front Chem)
Herein, a novel platform for anti-tumor drug delivery was developed by incorporating an amphiphilic stachydrine-octadecane conjugate (SS) as the mitochondria-targeting molecule onto the triptolide-liposome surfaces (SS-TP LPs)...In the Pan02 tumor-bearing mice, the SS-TP LPs showed significant efficacy in inhibiting tumor growth and reducing tumor size but synchronously exhibited specific mitochondria-targeting and much lower subacute toxicity compared with the free TP and TP LPs. Our study suggests that SS-TP LPs can be a promising anticancer drug delivery system for mitochondria-targeted therapy in pancreatic cancer.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
TriptoSar (omtriptolide)
3years
In vitro, in vivo and molecular effects of triptolide and minnelide in renal cell carcinoma (KCRS 2022)
The profound antitumor effects in the aggressive 786-0 RCC xenograft model are highly encouraging and warrant further preclinical studies and potential clinical trials of M this devastating disease. Correlative tumor studies to understand the mechanisms of M in vivo antitumor effects are underway and will be presented at the meeting.
Preclinical
|
CASP3 (Caspase 3) • EIF2A (Eukaryotic Translation Initiation Factor 2A) • EIF2S1 (Eukaryotic Translation Initiation Factor 2 Subunit Alpha)
|
minnelide • TriptoSar (omtriptolide)
3years
Novel EGFR/PI3K dual-targeting nanoparticles induce immunogenic cell death in bladder cancer (SITC 2022)
Methods Herein, we identified two natural products triptolide (TPL) and hesperidin (HSP), dual targeting EGFR and PI3Kin BCa by network pharmacology and molecular modeling...Immunogenic cell death markers HMGB1 and CRT levels were evaluated both in vitro and in vivo after treatment so as to inhibit BCa proliferation and tumor growth. Conclusions Dual targeting nanoparticle may emerge as a novel paradigm in BCa treatment, providing a new approach for inducing immunogenic cell death in BCa care.
EGFR (Epidermal growth factor receptor) • HMGB1 (High Mobility Group Box 1)
|
EGFR overexpression
|
TriptoSar (omtriptolide)
3years
The Antigastric Cancer Effect of Triptolide is Associated With H19/NF-κB/FLIP Axis. (PubMed, Front Pharmacol)
TP pretreatment increased apoptosis in TNF-α-stimulated gastric cancer cells, which are dependent on the disruption of the H19/miR-204-5p/NF-κB/FLIP axis. Cotreatment of TP and TNF-α is a better option for enhancing the anticancer effect and lowering the side effect of TP.
Journal
|
H19 (H19 Imprinted Maternally Expressed Transcript) • MIR204 (MicroRNA 204)
|
TriptoSar (omtriptolide)
3years
Regulation of dietary polyphenols on cancer cell pyroptosis and the tumor immune microenvironment. (PubMed, Front Nutr)
These dietary polyphenols include curcumin (CUR), resveratrol (RES), epigallocatechin gallate (EGCG), apigenin, triptolide (TPL), kaempferol, genistein and moscatilin...Dietary polyphenols are also used with radiotherapy and chemotherapy to improve antitumor immunity and shape a beneficial TIME. In conclusion, dietary polyphenols induce cancer cell pyroptosis and regulate the TIME, providing new ideas for safer cancer cures.
Review • Journal
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
TriptoSar (omtriptolide)
over3years
NCI-2021-12558: Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1b, N=30, Recruiting, City of Hope Medical Center | Initiation date: Jul 2022 --> Mar 2022
Trial initiation date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
|
Tagrisso (osimertinib) • minnelide • TriptoSar (omtriptolide)